Changes in motor function, quality of life, and clinical manifestations in patients with Alpha-mannosidosis treated with Velmanase Alfa: Data from the French Étoile Alpha registry Authors: Nathalie Guffon, Karine Mention-Mulliez, Francis Gaches, Daniela Garavaglia, Fabrizio Salomone, Bénédicte Héron Published: 2026 ABSTRACT Alpha-mannosidosis (AM) is a rare lysosomal storage disease with heterogeneous disease manifestations and a continuous spectrum of severity. The only specific treatment for AM is enzyme replacement therapy with velmanase alfa (VA). The focus of this analysis was to assess changes in physician-reported clinical manifestations of AM following VA treatment, using data from Étoile Alpha, a multicenter, non-interventional registry of AM patients treated with VA in France. The cohort included 16 patients (7 females [43.7%]) and 9 males [56.3%]), with a median (range) age at VA initiation and duration of VA treatment of 15.7 (6.1–49.4) and 3.3 (1.1–9.2) years, respectively. Clinical outcomes, including 3-minute stair climb test, 6-minute walk test, forced expiratory volume in 1 second and forced vital capacity, showed numerical improvements from baseline to the last assessment. VA treatment was associated with significant (p < 0.0001) improvements in overall physician-assessed health assessment scores, encompassing motor, quality of life and psychological domains. Across all individual clinical manifestations, VA led to either improvement or stability, with no deteriorations reported. Lower patient age at inclusion, diagnosis and at VA initiation were significantly (p < 0.05) associated with improvement of clinical manifestations. To complement these clinical data, physician-reported narratives recorded before and after VA treatment were evaluated using natural language processing. Sentiment analysis revealed that all pre-treatment narratives were negative, with shifting to positive sentiment in 81.3% of cases following treatment. This analysis highlights the varied clinical manifestations associated with AM and underscores the potential benefits of early intervention with enzyme replacement therapy. Introduction Alpha-mannosidosis (AM) is a rare lysosomal storage disease with an estimated prevalence of ∼1 in 500,000 [1], [2]. A deficiency in the lysosomal enzyme alpha-mannosidase leads to defective degradation of glycoproteins, accumulation of mannose-rich oligosaccharides in organs, impaired cellular function, and apoptosis [1]. AM is an autosomal recessive condition caused by pathogenic variants in the MAN2B1 gene [3], [4], and with around 183 AM-associated MAN2B1 variants, establishing clear genotype-phenotype correlations is challenging [5]. AM is a progressive multi-systemic disease with heterogeneous manifestations, making early diagnosis difficult. Common signs and symptoms of AM include speech delay and early-onset neurosensory hearing loss, recurrent infections, immunodeficiency, and motor coordination issues [6]. Disease severity exists on a spectrum with some patients presenting with more attenuated (e.g., mild/moderate) forms of AM and some with severe forms that can result in early death [6]. Considering the progressive nature of the disease, children typically experience developmental delays including learning difficulties and mild-to-moderate intellectual disability [7], [8]. Adults may face worsening ataxia, psychiatric manifestations, skeletal abnormalities, along with ocular issues and other complications [7], [8]. The diverse spectrum of clinical manifestations and progression of AM require that patients be assessed and treated on an individual basis. Current targeted treatment options are limited to hematopoietic stem cell transplantation (HSCT) and enzyme replacement therapy (ERT). HSCT has been shown to slow AM-associated cognitive decline when performed early [6] and patients treated with HSCT may show neurocognitive improvement [9], [10]. HSCT is generally more beneficial in younger patients and when administered before significant clinical deterioration. However, the potential benefits must be carefully weighed against the procedural risks associated with HSCT [6], [11]. Velmanase alfa (Chiesi Farmaceutici SpA, Parma, Italy), a recombinant human lysosomal alpha-mannosidase, is currently the only ERT available for the treatment of AM [12]. Velmanase alfa was approved in 2018 by the European Medicines Agency for the treatment of non-neurological manifestations in patients with mild-to-moderate AM. It was subsequently approved by the US Food and Drug Administration in 2023 for non-central nervous system manifestations of AM in adult and pediatric patients [12], [13]. The safety and efficacy of velmanase alfa has been evaluated across five Phase I–III clinical trials and long-term extensions with data up to 12 years indicating that treatment benefits of velmanase alfa are maintained in pediatric and adult patients with AM [14], [15], [16]. While clinical trial data provide critical evidence for treatment impact on standard clinical outcomes, complementary data derived from routine clinical practice contribute additional context on patient response and disease evolution. Such real-world clinical assessments may capture changes not fully reflected by conventional outcome measures, particularly in heterogeneous populations with wide variability in disease presentation and progression. The Étoile Alpha registry was established to gather long-term effectiveness and safety data of velmanase alfa and to expand the current understanding of AM and response to ERT. While clinical safety and efficacy data from this patient population have largely been published through the velmanase alfa clinical development program, the aims of the present analysis were to summarize the changes in clinical manifestations (e.g., signs/symptoms related or unrelated to disease) among patients with AM enrolled in the Étoile Alpha registry, and to characterize qualitative physician assessments of patients' clinical status before and after receiving velmanase alfa. As such, this study provides physician-assessed health assessment scores, encompassing motor, quality of life and psychological evaluation domains. A further aim was to assess the impact of baseline characteristics on changes in clinical manifestations following the start of velmanase alfa therapy. Methods Study design Étoile Alpha is a multicenter, non-interventional registry that includes patients with AM who have received at least 1 dose of velmanase alfa in France (previously enrolled in rhLAMAN-07 [NCT01908712], or rhLAMAN-08 [NCT02998879], or treated via nominative authorization for temporary use [ATU]). Patients were included if they had received velmanase alfa treatment (any dose) in France, and patients or legal guardians provided informed consent to participate in the registry and study efforts. Patients were excluded if they (or their legal guardian) were opposed to the collection of medical record data. Four sites in France participated (Lyon, Paris, Lille, and Toulouse). Here, we report retrospective patient data from the earliest available pre–velmanase alfa records through June 2020. The data collection period occurred from November 27, 2020, to May 26, 2021. Ethics The study was conducted in accordance with applicable local regulations and the principles outlined in the Declaration of Helsinki. The study protocol and all relevant documents received approval from the ethics committees of all participating centers. Signed informed consent was obtained from all patients who participated in this registry study to allow collection or use of their data in this study. Assessments The pre-treatment baseline was defined as the latest assessment available before the start of velmanase alfa therapy. As this was not an interventional study, no treatment compliance information is available. The collected patient data comprised laboratory results (including oligosaccharide and immunoglobulin G levels), tests of motor function (3-minute stair climb test [3MST], 6-minute walk test [6MWT]), pulmonary function tests (forced vital capacity [FVC], peak expiratory flow measurement [PEF], and forced expiratory volume in 1 second [FEV1]), and adverse event reporting. Outside of formal clinical tests, treating physicians provided written summaries of the condition of patients before and after treatment, which were per-protocol defined as ‘practitioner comment'. As part of the ‘practitioner comments', physicians provided their assessments as to whether there was decline or improvement (on a scale of −10 [worst decline] to +10 [best improvement]) in overall health assessment domains (motor function, psychological and quality of life) between 2 timepoints: before starting velmanase alfa and at the last follow-up after receiving velmanase alfa. These were collected at inclusion into the ATU/clinical study and at the last visit available before data collection. Investigators further indicated individual clinical manifestations for each patient, and physicians recorded whether there was improvement, stability, or deterioration associated with the manifestation at last follow-up after treatment with velmanase alfa. For analytical purposes, clinical manifestations were grouped into ten categories: cardiac; gastroenterological; neuromuscular; ophthalmic; pain; psychiatric; recurrent infections; respiratory; skeletal/osteoarticular; and ‘other.’ Percentages were calculated for improvement, stability, or deterioration within each category, and the percentage frequency of each category from the total was assessed (Supplementary Table 1). Statistical analysis Data on physician assessments were pooled, and post hoc statistical analyses were performed to compare outcomes before and after treatment; the analyses included both quantitative and qualitative components. Quantitative analysis included analysis of variance (ANOVA), paired t-tests, Chi-squared tests, and logistic regression to identify key factors contributing to improvements or stability post-treatment. The analysis was conducted using Python™ (Python Software Foundation, Delaware, US). ANOVA was applied to compare outcomes across clinical manifestations. Chi-squared tests were used to assess associations between clinical conditions and treatment outcomes, with residuals calculated for detailed insights. t-tests examined the association between demographic variables and clinical outcomes, with the Benjamini-Hochberg procedure to account for the increased risk of false positives arising from multiple statistical comparisons. Logistic regression models explored the influence of variables such as age and the association of clinical manifestations on post-velmanase alfa treatment outcomes. For the qualitative analysis, text was extracted from the physician summaries of the condition of patients before and after treatment (available in Supplementary Table 2) for thematic exploration. Thematic analysis was performed using a natural language processing (NLP) workflow specifically developed to systematically extract key topics and sentiments from text narratives. A large language model was used to conduct structured thematic analysis on the extracted text data. To enhance transparency and interpretability, each identified theme was explicitly labeled with its corresponding sentiment (positive, negative, or neutral) and accompanied by a brief rationale for the sentiment assignment. Sentiment determinations could then be directly linked to specific themes and supporting text excerpts. The results were visualized using word clouds, and sentiment shifts before and after treatment were quantified as percentage changes. Results Patient demographics Individual and overall patient characteristics are reported in Table 1. The cohort included 16 patients with AM: 7 patients previously enrolled in rhLAMAN-07 (NCT01908712), 1 patient previously enrolled in rhLAMAN-08 (NCT02998879), and 8 patients treated under nominal ATU. The cohort was relatively balanced in terms of gender, with 9 males (56.3%) and 7 females (43.7%). The median age of patients at AM diagnosis was 4.6 (range, 2.1–42.8) years, whereas the median age at velmanase alfa initiation was 15.7 (range, 6.1–49.4) years. Fourteen of the 16 patients (87.5%) were diagnosed before the age of 10, while only 5 patients (31.3%) started receiving velmanase alfa before this age. Notably, nearly half of the cohort (7/16, 43.8%) started therapy as an adult owing to the availability of velmanase alfa. At the time of last follow-up, all patients had received velmanase alfa for at least 1 year, with 1 patient having been treated for nearly a decade.Table 1Patient characteristics.PatientAge at inclusion (years)SexDate velmanase alfa initiatedAge at time of diagnosis (years)Age at velmanase alfa initiation (years)Duration of velmanase alfa use (years)010111.5M20174.37.83.3010215.0M20179.111.33.3010345.9F20183.743.32.2010415.8F20105.316.09.2010528.4M20132.129.66.6010617.9F20124.218.17.601077.6M20122.37.87.601086.0M20174.86.13.2010938.1M20173.934.41.1011017.1F20142.918.46.4011112.6M20138.712.97.401128.3F20116.18.47.5020112.5M20172.89.22.8030118.8F20178.515.41.2040133.9F201815.631.12.0040252.1M201842.849.41.9Summary statistics, N=1616.4 (6.0–52.1)F: 7 (43.7)* M: 9 (56.3)*–4.6 (2.1–42.8)15.7 (6.1–49.4)3.3 (1.1–9.2)Summary statistics are median (range) unless otherwise indicated; *n (%). F, female; M, male. Table 1Patient characteristics.PatientAge at inclusion (years)SexDate velmanase alfa initiatedAge at time of diagnosis (years)Age at velmanase alfa initiation (years)Duration of velmanase alfa use (years)010111.5M20174.37.83.3010215.0M20179.111.33.3010345.9F20183.743.32.2010415.8F20105.316.09.2010528.4M20132.129.66.6010617.9F20124.218.17.601077.6M20122.37.87.601086.0M20174.86.13.2010938.1M20173.934.41.1011017.1F20142.918.46.4011112.6M20138.712.97.401128.3F20116.18.47.5020112.5M20172.89.22.8030118.8F20178.515.41.2040133.9F201815.631.12.0040252.1M201842.849.41.9Summary statistics, N=1616.4 (6.0–52.1)F: 7 (43.7)* M: 9 (56.3)*–4.6 (2.1–42.8)15.7 (6.1–49.4)3.3 (1.1–9.2)Summary statistics are median (range) unless otherwise indicated; *n (%). F, female; M, male. Patient characteristics. Summary statistics are median (range) unless otherwise indicated; *n (%). F, female; M, male. Clinical outcomes and safety in the Étoile Alpha registry The efficacy and safety of velmanase alfa have been previously reported in detail for patients enrolled in the long-term clinical trials rhLAMAN-07 (NCT01908712) and rhLAMAN-09 (NCT01908725) [16]. Approximately half of the patients in the Étoile Alpha registry were drawn from these earlier trials, and therefore contributed data to the wider real-world follow-up cohort [16]. As such these outcomes are not the focus of the present analysis. Descriptive statistics for efficacy endpoints covering assessments of walking, respiratory function, and biochemical response are available in the Supplementary Results, including Supplementary Tables 3–5 and Supplementary Fig. 1 and 2. Consistent with findings from previous clinical trials, registry data demonstrated sustained improvements with velmanase alfa treatment including increased walking distance or endurance, improvements in respiratory function and favorable biochemical changes such as reductions in serum and urine oligosaccharides levels and increases in immunoglobulin G (IgG), reinforcing the biochemical response to therapy over time. Regarding safety, the registry data captured a total of 69 adverse events (AEs) in 8 patients over the follow-up period. Of these, 12 events (17.4%) occurring in 3 patients (18.7%) were considered related to velmanase alfa, as determined by the treating physician (Supplementary Table 6). The majority of treatment-related AEs (8/12, 66.6%) occurring in 1 patient including 2 severe infusion related reactions that led to treatment discontinuation (edemas of eyelids and tongue, and predominant exanthems on face and trunk). All treatment-related AEs subsequently were resolved. Physician-reported assessments Quantitative assessments Health assessment scores Health assessment scores encompassing motor, quality of life, and psychological evaluation domains and individual patient-level clinical manifestations were evaluated after treatment with velmanase alfa relative to pre-treatment baseline. Health assessment scores showed significant improvements (2-tailed paired t-test, p < 0.0001) after treatment with velmanase alfa. The mean ± standard deviation (SD) score changes following treatment were 7.0 ± 3.7, 9.8 ± 4.7 and 7.7 ± 5.0 for the motor, quality of life and psychological evaluation domains, respectively (Fig. 1).Fig. 1Changes in health assessment scores before and after treatment for (A) motor, (B) quality of life and (C) psychological evaluations.***p < 0.0001, paired t-test.Score based on a scale of −10 [worst decline] to +10 [best improvement]. Physicians evaluated each patient on 3 overall health assessment domains (motor function, psychological and quality of life) exploiting available clinical tests results at 2 timepoints: before starting velmanase alfa and at the last follow-up after receiving velmanase alfa.Fig. 1 Changes in health assessment scores before and after treatment for (A) motor, (B) quality of life and (C) psychological evaluations. ***p < 0.0001, paired t-test. Score based on a scale of −10 [worst decline] to +10 [best improvement]. Physicians evaluated each patient on 3 overall health assessment domains (motor function, psychological and quality of life) exploiting available clinical tests results at 2 timepoints: before starting velmanase alfa and at the last follow-up after receiving velmanase alfa. Clinical manifestation outcomes following velmanase alfa treatment In the cohort combined, 47.4% of reported manifestations were associated with improvement, while 52.6% were associated with stability, with no manifestations associated with deterioration. A heatmap of the frequencies of manifestation categories, split by improvement and stability, is shown in Fig. 2. Overall, neuromuscular manifestations were the most numerous, accounting for 47.8% of all clinical manifestations. Of these neuromuscular manifestations, 48.7% remained stable while 51.3% were associated with improvement following velmanase alfa treatment. Skeletal/osteoarticular manifestations were the second most frequent, and were mostly stable after velmanase alfa treatment, accounting for 24.1% of stability outcomes vs 8.2% of improvement outcomes. Other categories generally saw improvement after velmanase alfa treatment. In particular, the cardiac category (which largely comprised structural heart conditions, such as aortic valvulopathy, mitral valvulopathy, and left ventricular hypertrophy) comprised 3.6% of the total clinical manifestations, two-thirds of which were considered improved post-velmanase alfa. Before velmanase alfa treatment, 5 patients developed mitral or aortic valvulopathy at a median age of 15.5 years (range 7.5–40 years) and 4 patients developed left ventricular hypertrophy at a median age of 17.5 years (range 10–43 years). After velmanase alfa treatment, at last follow-up, valvulopathy remained stable in 3 patients and improved in 2; 3 patients had no more left ventricular hypertrophy and 1 improved. Statistical analysis confirmed a significant association between treatment outcomes (stability or improvement) and clinical manifestation group, with a Chi-square value of 38.3 (p < 0.00001), indicating a significant relationship between the manifestation group and velmanase alfa treatment outcomes.Fig. 2A heatmap of clinical manifestation categories by outcome following velmanase alfa treatment as a percentage of (A) all clinical manifestations and (B) within each category.Fig. 2 A heatmap of clinical manifestation categories by outcome following velmanase alfa treatment as a percentage of (A) all clinical manifestations and (B) within each category. Influence of demographic factors on treatment outcomes We assessed the influence of patient demographics on clinical outcomes following velmanase alfa through a series of statistical analysis. As a first step, we conducted a correlation analysis (Supplementary Fig. 3), coding outcomes as 1 for improvement and 0 for stability. This indicated weak, but statistically significant, inverse correlations between the outcomes and patient age at inclusion (−0.17, p = 0.006), age at time of diagnosis (−0.13, p = 0.027) and age at first velmanase alfa exposure (−0.16, p = 0.006), suggesting that younger age at velmanase alfa initiation is associated with better outcomes. Chi-square analysis suggested associations between individual demographic factors and clinical manifestations. Younger age at diagnosis significantly influenced gastroenterological and neuromuscular manifestations (Chi-square values: 65.5 [p = 0.02] and 66.5 [p = 0.02], respectively). Age at velmanase alfa initiation significantly impacted gastroenterological, neuromuscular, and respiratory outcomes (Chi-square values: 64.5 [p = 0.01], 65.1, [p = 0.01], 60.4 [p = 0.03], respectively), while treatment duration was also associated with these manifestations (Chi-squares values: 64.8 [p = 0.01], 65.3 [p = 0.01], 60.7 [p = 0.03], respectively). While these tests indicated an association, they do not specify the directionality (i.e., improvement vs stability) of the observed outcomes. When examining specific clinical manifestations, certain demographic factors showed a notable association with improved outcomes. For patients with delayed motor skill development, longer velmanase alfa use was associated with improvement outcomes (T-statistic, 2.25; p = 0.05). Among patients with language delay, younger age at inclusion (T-statistic, −2.32, p = 0.04) and earlier treatment initiation (T-statistic, −2.43, p = 0.04) were both significantly associated with better outcomes (Table 3). These results may suggest that earlier and sustained intervention with velmanase alfa may enhance clinical improvements, particularly in developmental domains. Qualitative assessments NLP identified 5 themes before treatment and 5 after treatment from the physician narratives (Table 2). Themes before treatment were largely related to the health challenges (physical, psychological and cognitive) that the patients were living with and were all associated with a negative sentiment. In contrast, themes after treatment were all related to improvement in physical, psychological, and cognitive symptoms and all were associated with positive sentiments. The most prominent words associated with themes before treatment were ‘health’, ‘physical’, and ‘challenges’. Additionally, ‘physical’ was also a prominent word for themes after treatment, but was accompanied by words denoting improvement. NLP determined the sentiment of all physician narratives before treatment to be negative; after treatment, there was a sentiment shift from negative to positive in the majority (81.3%) of patients. The remaining patients had an overall sentiment shift from negative to ‘mixed’; there were no incidents where the sentiment of narratives remained negative. A full list of anonymized investigator narratives and remarks regarding each patient before and after treatment is provided in Supplementary Table 2.Table 2Themes before and after velmanase alfa treatment with associated sentiments from 16 physician narratives.ThemeDescriptionSentimentBefore treatmentPhysical and motor challengesThe patient experienced significant physical and motor issues, including balance and coordination disorders, frequent falls, hypotonia, and joint painNegative: These physical limitations severely impacted the patients' mobility and quality of lifeCognitive and language delaysThese cognitive and language issues affected educational progress and social interactionsNegative: These cognitive and language issues affected educational progress and social interactionsFatigue and lack of autonomyThe patients experienced fatigue, required frequent naps, and lacked autonomy appropriate for their ageNegative: The fatigue and lack of autonomy limited daily functioning and independenceHealth complicationsThe patients suffered from frequent infections (including ear, nose and throat, and respiratory issues) and required medical aids like a corsetNegative: Frequent health issues contributed to a poor quality of life and increased medical concernsMental health challengesThe patients suffered from anxiety, depression, and behavioral disordersNegative: Frequent health issues contributed to a poor quality of life and increased medical concerns After treatmentAlleviation of physical symptomsThe patients reported improved balance, motor skills, and no longer needed a corsetPositive: Improvements in physical abilities enhanced the patients' quality of life and independenceCognitive and language improvementsThe patients showed significant improvement in oral and written language skillsPositive: The cognitive and language progress indicates better educational and social opportunitiesIncreased autonomy and energyThe patients achieved normal autonomy for his age and experienced reduced fatiguePositive: Increased autonomy and energy levels improved daily functioning and engagement in activitiesResolution of health issuesThe patients had no new infections and stopped using medical aids like a corsetPositive: The absence of health issues reflects a stable and improved health conditionEnhanced mental and emotional well-beingThe patients experienced decreased anxiety, improved morale, and better social interactionsPositive: Improvements in mental health and social engagement contributed to a better quality of lifeTable 3Association of demographic factors with treatment outcomes across clinical manifestations.Clinical manifestationDemographic variableT-statisticP-valueAdjusted P-valueSignificance (false discovery rate)Delay in the development of motor skillsDuration of VA exposure2.2548020.0458310.2994FalseLanguage delayAge at inclusion−2.3238710.0442820.2994FalseLanguage delayAge at VA exposure−2.4328340.0356560.2994FalseVA, velmanase alfa. Table 2Themes before and after velmanase alfa treatment with associated sentiments from 16 physician narratives.ThemeDescriptionSentimentBefore treatmentPhysical and motor challengesThe patient experienced significant physical and motor issues, including balance and coordination disorders, frequent falls, hypotonia, and joint painNegative: These physical limitations severely impacted the patients' mobility and quality of lifeCognitive and language delaysThese cognitive and language issues affected educational progress and social interactionsNegative: These cognitive and language issues affected educational progress and social interactionsFatigue and lack of autonomyThe patients experienced fatigue, required frequent naps, and lacked autonomy appropriate for their ageNegative: The fatigue and lack of autonomy limited daily functioning and independenceHealth complicationsThe patients suffered from frequent infections (including ear, nose and throat, and respiratory issues) and required medical aids like a corsetNegative: Frequent health issues contributed to a poor quality of life and increased medical concernsMental health challengesThe patients suffered from anxiety, depression, and behavioral disordersNegative: Frequent health issues contributed to a poor quality of life and increased medical concerns After treatmentAlleviation of physical symptomsThe patients reported improved balance, motor skills, and no longer needed a corsetPositive: Improvements in physical abilities enhanced the patients' quality of life and independenceCognitive and language improvementsThe patients showed significant improvement in oral and written language skillsPositive: The cognitive and language progress indicates better educational and social opportunitiesIncreased autonomy and energyThe patients achieved normal autonomy for his age and experienced reduced fatiguePositive: Increased autonomy and energy levels improved daily functioning and engagement in activitiesResolution of health issuesThe patients had no new infections and stopped using medical aids like a corsetPositive: The absence of health issues reflects a stable and improved health conditionEnhanced mental and emotional well-beingThe patients experienced decreased anxiety, improved morale, and better social interactionsPositive: Improvements in mental health and social engagement contributed to a better quality of life Themes before and after velmanase alfa treatment with associated sentiments from 16 physician narratives. Table 3Association of demographic factors with treatment outcomes across clinical manifestations.Clinical manifestationDemographic variableT-statisticP-valueAdjusted P-valueSignificance (false discovery rate)Delay in the development of motor skillsDuration of VA exposure2.2548020.0458310.2994FalseLanguage delayAge at inclusion−2.3238710.0442820.2994FalseLanguage delayAge at VA exposure−2.4328340.0356560.2994FalseVA, velmanase alfa. Association of demographic factors with treatment outcomes across clinical manifestations. VA, velmanase alfa. Discussion and conclusions Clinically meaningful treatment outcomes for patients with AM are focused on either disease stabilization or improvement, and includes changes in the disease course such as an absence of respiratory infections or slowing of a patient's overall clinical decline [17]. Real-world data from the French Étoile Alpha registry provides additional evidence on the effectiveness of velmanase alfa in achieving these goals, extending observations from 5 Phase I–III clinical studies that have previously established the safety and efficacy of velmanase alfa in adult and pediatric (≥6 years old) patients with AM for up to 12 years [14], [15], [16]. Building on this, the use of observer-reported data to generate real-world evidence is increasingly recognized as essential in rare disease research, where selecting meaningful outcomes is particularly challenging [18]. This difficulty often arises due to heterogenous populations, small sample sizes and complex disease presentation, which can confound more traditional outcomes. Therefore, this analysis sought to assess treatment response at the level of individual disease manifestations by analyzing physician-reported global health assessments systematically collected in the Étoile Alpha registry. These physician-reported evaluations indicate that velmanase alfa treatment resulted in stability or improvement in a wide range of clinical manifestations, and importantly, no deteriorations were reported. These findings are consistent with a recent retrospective analysis of 25 patients with AM, in which all patients receiving velmanase alfa demonstrated stable or improved clinical status [19]. Similar to prior work characterizing the clinical spectrum of AM, motor impairment was more frequently observed in patients with milder disease, whereas intellectual disability was more prevalent in those with moderate-to-severe disease. In the current analysis, neuromuscular manifestations constituted the largest category of reported clinical features, with approximately half of patients exhibiting improvement following initiation of velmanase alfa therapy. Due to the small registry sample size, no formal statistical analyses were performed on the standard clinical assessments. However, numerical improvements were seen between baseline and last month of evaluation for a number of parameters including 3MSCT and 6MWT, with no evidence of overall decline in these parameters. When taken in the context of the age of the participants and the progressive nature of the disease, the lack of decline in the walking tests is in itself a positive result. Of note, in the long-term velmanase alfa trials, improvement in 3MSCT score was more pronounced in pediatric patients, demonstrating the impact of patient age on these parameters [15]. The improvement in respiratory tests observed in this study was also seen in the integrated analysis of long-term efficacy data, with pediatric patients demonstrating the largest improvement in absolute change in FVC [15]. Overall, both the registry-based evaluation of individual clinical manifestations and clinical data align with results from the rhLAMAN-07/rhLAMAN-09 studies, where numerical improvements in 6MWT, 3MSCT, and FVC, as well as serum oligosaccharides and IgG were also observed [16]. Direct comparisons of safety outcomes between the registry and clinical trials are limited by differences in data collection and reporting methodologies. Not only is AM a progressive disease that worsens over time, but also exhibits considerable heterogeneity in clinical presentation [17], as reflected in the diverse range of manifestations recorded for each patient. These were primarily neuromuscular and skeletal/osteoarticular in nature; however, many other systems were noted to have been affected as patients presented with cardiac, respiratory, gastroenterological, psychiatric, ophthalmic, pain, and infection-related clinical manifestations. Neurological decline is associated with AM disease progression [20], [21], with clinical signs typically emerging early in life [21] and leading to muscular weakness, joint abnormalities, and ataxia [4]. In the present study, neurological signs/symptoms were frequently improved or remained stable; notably 1 patient began verbalizing and talking after around 20 years of being non-verbal. This suggests that velmanase alfa may help to slow the progression of neuromuscular involvement in AM. Both children and adults with AM frequently exhibit mild-to-moderate skeletal abnormalities on radiographic imaging with scoliosis and deformity of the sternum being among the most frequently observed features [5]. Given the structural nature of these manifestations and the limited potential for reversal of established skeletal deformities, it is not unexpected that skeletal/osteoarticular symptoms were more likely to remain stable rather than improve following velmanase alfa treatment. Nevertheless, stability of these manifestations over time is a clinically meaningful outcome given that AM is a degenerative disorder. A category that showed a high level of improvement was ‘cardiac’ (66.7%). Although these manifestations comprised only 3.6% of the total number of clinical manifestations, they were observed in 6/16 patients (38%) and encompassed structural cardiac abnormalities that are clinically important. Cardiac issues are seen more frequently in older patients with AM [6] and there are few data on the impact of velmanase alfa on these conditions. One study in mice found that ERT can clear oligosaccharides in the myocardium [22]; together with results presented here, the treatment impact on cardiac conditions in AM warrants further study. When analyzing factors that influence post-velmanase alfa outcomes, patient age at follow-up, at diagnosis and at treatment initiation were all important predictors of whether clinical manifestations improved. These findings emphasize the importance of patient age and age at first velmanase alfa exposure as predictors. This is in line with the long-term findings of a multicenter study of 16 patients with AM that concluded early ERT initiation may lead to a better clinical outcome [23]. Additionally, the rhLAMAN-07/rhLAMAN-09 studies indicated that there was a delay in clinical worsening in patients who initiated treatment at a pediatric age [15], [16]. For many of the adult patients in the registry, velmanase alfa treatment was unavailable for much of their lives, with several of the patients having a higher age at enrollment. Therefore, it is of interest that age at initiation and the duration of velmanase alfa exposure significantly influenced a variety of clinical manifestations including those classed gastroenterological, neuromuscular, and respiratory. While modest effects were observed in rhLAMAN-05 after a mean (SD) treatment exposure of 29.3 (15.2) months, the longer-term findings from rhLAMAN-07/rhLAMAN-09, with median (range) velmanase alfa exposure durations of 9.2 (1.1–11.8) years in pediatric patients (n = 14) and 8.8 (0.1–9.8) years in adult patients (n = 7), provide stronger evidence of therapeutic benefit. [15], [16], [17]. An additional component of the present study was the qualitative analysis of physician-reported global health status assessments collected within the Étoile Alpha registry. To our knowledge, this represents the first application of a thematic analytical approach to assess longitudinal changes in patients with AM after treatment with velmanase alfa. Following initiation of velmanase alfa therapy, clinician-reported assessments consistently reflected stabilization or improvement across identified thematic domains, with no assessments indicating overall clinical deterioration. These findings suggest a favorable shift in patients' functional status, including increased ability to perform activities of daily living. These observations are in line with previous research into the effects of velmanase alfa on quality of life of patients with AM where improvements in both quality of life and a general reduction in disability were seen in pediatric patients [24]. Several limitations to this study should be noted. Although a common occurrence in studies of rare disease, half of the patients that contributed data were previously enrolled in the velmanase alfa clinical development program and subsequently transitioned into the Étoile Alpha registry for continued long-term follow-up [16]. The study was conducted using a retrospective chart review approach, which may have led to incomplete or missing data. Physician-reported global health assessments, are limited by reliance on evaluations conducted outside of formalized, standardized clinical testing. This is inclusive of the data captured in Fig. 1, which although reflects the quantitative scoring approach used in the physician evaluations, was not based on a validated clinical instrument. As such, these assessments primarily reflect clinicians' observations and may not capture all objective measures of patient status. In addition, physician evaluations could potentially have been influenced by awareness that patients were receiving a disease-modifying therapy. Nevertheless, the recurrence of similar terminology across independent patient narratives documented by different physicians strengthens confidence in the validity of the findings. Another inherent limitation, common in rare disease research, is the small sample size, which may affect the generalizability of the findings and may reduce the reliability of statistical inferences. In conclusion, this analysis of the Étoile Alpha registry provides real-world evidence on the impact of velmanase alfa in patients with AM, expanding upon the clinical trial data previously reported. Uniquely, this study offers the first systematic evaluation of physician-reported outcomes across a broad spectrum of clinical manifestations in a real-world setting, including domains such as neuromuscular, respiratory, and gastroenterological involvement. Importantly, the analysis suggests that velmanase alfa was associated with either stabilization or improvement in clinical manifestations, with no cases of clinical deterioration reported. This is particularly relevant for a progressive condition like AM, where halting disease progression is itself a meaningful outcome. The results also highlight, for the first time in a registry context, that earlier age at treatment initiation and longer treatment duration are associated with more favorable outcomes, reinforcing the importance of timely intervention. CRediT authorship contribution statement Nathalie Guffon: Writing – review & editing, Investigation, Data curation, Conceptualization. Karine Mention-Mulliez: Writing – review & editing, Investigation. Francis Gaches: Writing – review & editing, Investigation. Daniela Garavaglia: Writing – review & editing, Formal analysis. Fabrizio Salomone: Writing – review & editing, Data curation. Bénédicte Héron: Writing – review & editing, Investigation. Ethics approval This study was designed and implemented in accordance with the Guide on Methodological Standards in Pharmacoepidemiology (Revision 3, July 2014) of the European Network of Centers for Pharmacoepidemiology and Pharmacovigilance (ENCePP), the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines, with the ethical principles laid down in the Declaration of Helsinki (1964 and amendments) and with the laws and regulations of each country in which the research is carried out. The study was conducted in full conformance with the principles of the current ICH E6 (R2) Good Clinical Practice (GCP), and with the laws and regulations of France. Funding This study was funded by Chiesi SAS. The Étoile Alpha Registry was funded by Chiesi France. Declaration of competing interest NG has received hospital grants and is PI in trials from Chiesi Pharmaceuticals SpA, Biomarin, JCR Pharmaceuticals, Sanofi, Takeda, and Ultragenyx Pharmaceutical Inc. She has received travels fees, accommodation, or honoraria from Chiesi Pharmaceuticals SpA, Biomarin, JCR Pharmaceuticals, RegenXbio, Sanofi, Takeda, and Ultragenyx Pharmaceutical Inc. BH has received honoraria from Takeda and Orchard; travel fees and accommodation from Chiesi Pharmaceuticals SpA and PTC Therapeutics; PI in trials sponsored by JR Pharmaceuticals, Chiesi Pharmaceuticals SpA, Orphazyme, Lysogene and Mallincrodt. DG and FS are employees of Chiesi Pharmaceuticals SpA/Chiesi SAS. KM and FG declare no conflicts of interest.